Eliane Sardh

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Journal article: ORPHANET JOURNAL OF RARE DISEASES. 2024;19(1):365
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
Sardh E; Balwani M; Rees DC; Anderson KE; Jia G; Sweetser MT; Wang B
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(4):675-686
Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study
Mantel A; Vassiliou D; Lissing M; Stephansson O; Wahlin S; Sardh E
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(2):286-299
Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals
Lissing M; Vassiliou D; Floderus Y; Harper P; Yan J; Hagstrom H; Sardh E; Wahlin S
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):824-836
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals
Lissing M; Vassiliou D; Floderus Y; Harper P; Bottai M; Kotopouli M; Hagstrom H; Sardh E; Wahlin S
Article: LIVER INTERNATIONAL. 2022;42(1):161-172
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiro P; Bissell DM; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):81-94
Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies
Vassiliou D; Sardh E
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2021;110(5):1250-1260
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver
Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2021;100(9):1712-1721
Treatment with assisted reproduction technologies in women with acute hepatic porphyria
Vassiliou D; Hirschberg AL; Sardh E
Article: GENOME MEDICINE. 2021;13(1):40
Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients
Stranneheim H; Lagerstedt-Robinson K; Magnusson M; Kvarnung M; Nilsson D; Lesko N; Engvall M; Anderlid B-M; Arnell H; Johansson CB; Barbaro M; Bjorck E; Bruhn H; Eisfeldt J; Freyer C; Grigelioniene G; Gustavsson P; Hammarsjo A; Hellstrom-Pigg M; Iwarsson E; Jemt A; Laaksonen M; Enoksson SL; Malmgren H; Naess K; Nordenskjold M; Oscarson M; Pettersson M; Rasi C; Rosenbaum A; Sahlin E; Sardh E; Stodberg T; Tesi B; Tham E; Thonberg H; Tohonen V; von Dobeln U; Vassiliou D; Vonlanthen S; Wikstrom A-C; Wincent J; Winqvist O; Wredenberg A; Ygberg S; Zetterstrom RH; Marits P; Soller MJ; Nordgren A; Wirta V; Lindstrand A; Wedell A
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(24):2289-2301
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani M; Sardh E; Ventura P; Peiro PA; Rees DC; Stoelzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang J-D; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L
Article: HEPATOLOGY. 2020;71(5):1546-1558
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stoelzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach J-C; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2019;380(6):549-558
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
Article: JOURNAL OF INTERNAL MEDICINE. 2018;284(1):78-91
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver
Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec J-Y; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach J-C; Puy H; Peoc'h K; Manceau H; Gouya L
Article: JOURNAL OF PROTEOMICS. 2015;127(Pt B):377-385
Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria
Serrano-Mendioroz I; Sampedro A; Isabel Mora M; Mauleon I; Segura V; Enriquez de Salamanca R; Harper P; Sardh E; Jose Corrales F; Fontanellas A
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2013;36(6):1063-1071
High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria
Sardh E; Wahlin S; Bjornstedt M; Harper P; Andersson DEH
Article: PLOS ONE. 2012;7(3):e32978
Renal Failure Affects the Enzymatic Activities of the Three First Steps in Hepatic Heme Biosynthesis in the Acute Intermittent Porphyria Mouse
Unzu C; Sampedro A; Sardh E; Mauleon I; Enriquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
Article: TRANSPLANT INTERNATIONAL. 2010;23(6):e18-e21
Combined liver and kidney transplantation in acute intermittent porphyria
Wahlin S; Harper P; Sardh E; Andersson C; Andersson DEH; Ericzon B-G
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2009;20(2):201-207
Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks
Sardh E; Harper P; Andersson DEH; Floderus Y
Article: CELLULAR AND MOLECULAR BIOLOGY. 2009;55(1):66-71
PORPHYRIN PRECURSORS AND PORPHYRINS IN THREE PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA AND END-STAGE RENAL DISEASE UNDER DIFFERENT THERAPY REGIMES.
Sardh E; Andersson DEH; Henrichson A; Harper P
Article: CLINICAL PHARMACOKINETICS. 2007;46(4):335-349
Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion
Sardh E; Rejkjaer L; Andersson DEH; Harper P
Article: CLINICAL CHEMISTRY. 2006;52(4):701-707
Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DEH; Harper P
Article: INFLAMMATION. 2002;26(6):291-296
Modulation of plasma levels of soluble adhesion molecules and nitric oxide in healthy volunteers by exposure to swine dust
Kölbeck KG; Sardh E; Gyllenhammar H; Palmberg L; Larsson K; Palmblad J
Visa fler

Alla övriga publikationer

Editorial comment: CANCERS. 2023;15(3):795
Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review
Lissing M; Vassiliou D; Harper P; Sardh E; Wahlin S
Review: EXPERT REVIEW OF GASTROENTEROLOGY AND HEPATOLOGY. 2022;16(9):879-894
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran
Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli M-J; Sweetser MT; Petrides PE
Letter: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;112(1):24
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
Bins S; Sardh E; Langendonk JG
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(5):593-610
RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria
Sardh E; Harper P
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;290(4):928-930
Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase
Vassiliou D; Sardh E
Other: CLINICAL CASE REPORTS. 2020;8(12):2483-2487
Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report
Vassiliou D; Lempessi C; Harper P; Sardh E
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2020;383(20):1989-1990
Givosiran for Acute Intermittent Porphyria REPLY
Balwani M; Sardh E; Gouya L
Review: EXPERT OPINION ON ORPHAN DRUGS. 2014;2(4):349-368
Management of acute intermittent porphyria
Harper P; Sardh E
Thesis / dissertation: 2008
Acute intermittent porphyria : studies of chronic disease, recombinant enzyme therapy and late complications
Sardh, Eliane

Anställningar

Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för klinisk forskning o utbildning, Södersjukhuset, Karolinska Institutet, 2008
Läkarexamen, Karolinska Institutet, 1995

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI